Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Antibody Drug Conjugates Market Heading Into 2029?

The size of the antibody drug conjugates market has experienced rapid expansion over the past few years. Expected to rise from $13.57 billion in 2024 to $16.53 billion in 2025, it predicts a compound annual growth rate (CAGR) of 21.8%. Factors such as the growing incidence of cancer, successful clinical trials and approvals, strategic alliances, increased R&D investments, and market growth strategies have played a significant role in the historical growth of this market.

There’s an expectation that the antibody drug conjugates market will experience a rapid expansion in the coming years. By 2029, it is projected to escalate to $37.9 billion, demonstrating a compound annual growth rate (CAGR) of 23.1%. The predicted growth in this phase can be linked to factors such as the emergence of next-generation ADCS, a broadening spectrum of indications, a growing push towards personalized medicine, enhanced investments in precision medicine, and escalated healthcare cognizance. The period ahead is also expected to see key trends such as advancements in conjugation technologies, deepened comprehension of tumor biology, technological innovation, the widening scope of therapeutic application, and further developments in conjugation technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2569&type=smp

Which Factors Are Pushing The Antibody Drug Conjugates Market Forward?

The worldwide increase in cancer cases is propelling the antibody-drug conjugates market forward. Major factors leading to most cancers are obesity, smoking, alcohol consumption, and unhealthy food consumption. According to Cancer Research UK, the annual number of new cancer cases is projected to reach 27.5 million by 2040. This surge in cancer cases is likely to boost the need for antibody-drug conjugates, promoting the expansion of the market.

Which Segment Held The Largest Share In The Antibody Drug Conjugates Market In 2025?

The antibody drug conjugates market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types

2) By Product: Adcertis, Kadcyla, Other Products

3) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology

4) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications

5) By End User: Hospital, Clinics, Other End Users

Subsegments:

1) By Monoclonal Antibodies: IgG-based Monoclonal Antibodies, IgM-based Monoclonal Antibodies, Bispecific Antibodies

2) By Linker: Cleavable Linkers, Non-cleavable Linkers, Stable Linkers

3) By Drug/Toxin: Cytotoxic Drugs, Chemotherapeutic Agents, Radioisotopes

4) By Other Types: Enzyme-Targeted ADCs, Antibody-Drug Conjugates with Immune Modulators

How Are Key Trends Driving Expansion In The Antibody Drug Conjugates Industry?

The focus of businesses in the analgesics market is shifting towards investment as a means to achieve growth. Key producers of pain-relieving drugs are investing in businesses at the clinical stage to secure a competitive edge and bolster their market presence. Such investments assist companies in extending their geographical reach and acquiring specialized knowledge in the innovation and production of new products. For example, a clinical-stage biopharmaceutical firm based in the US, Concentric Analgesics, Inc., announced in January 2022 that it had successfully closed a $20 million convertible note financing from a mix of new and existing investors. This capital will carry forward the Phase 3 studies for Vocacapsaicin, the company’s leading product candidate that’s ready for Phase 3. It will also fund further Phase 3 developmental activities for Vocacapsaicin, the company’s prime candidate for managing post-surgical pain. This financing marks a significant milestone for Concentric Analgesics, as it allows the company to persist in propelling Vocacapsaicin into Phase 3 development and it is a crucial initial step in gathering full financial support for the program up until NDA submission.

Which Organizations Are Driving Progress In The Antibody Drug Conjugates Industry?

Major companies operating in the antibody drug conjugates market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Zydus Lifesciences Limited, Seagen Inc., Seagen Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Eisai Co. Ltd., Merck KGaA

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Antibody Drug Conjugates Industry?

North America was the largest region in the antibody-drug conjugates (ADCs) market in 2024. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2569&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model